Vote No. 263

Motion by Mr. Woodall to add a section to the rule that provides it shall be in order at any time through March 12, 2020, for the Speaker to entertain motions that the House suspend the rules relating to the bill (H.R. 5133) to prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market, as ordered reported from the Committee on the Judiciary. Defeated: 4–7